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Vascular endothelial growth factor C (VEGF-C) is a
potent lymphangiogenic cytokine that signals via
the coordinated action of two cell surface receptors,
Neuropilin-2 (Nrp2) and VEGFR-3. Diseases associ-
atedwith both loss and gain of VEGF-C function, lym-
phedema and cancer, respectively, motivate studies
of VEGF-C/Nrp2 binding and inhibition. Here, we de-
monstrate that VEGF-C binding to Nrp2 is regulated
by C-terminal proteolytic maturation. The structure
of the VEGF-C C terminus in complex with the ligand
binding domains of Nrp2 demonstrates that a cryptic
Nrp2 binding motif is released upon proteolysis, al-
lowing specific engagement with the b1 domain of
Nrp2. Based on the identified structural requirements
for Nrp2 binding to VEGF-C, we hypothesized that
the endogenous secreted splice form of Nrp2,
s9Nrp2, may function as a selective inhibitor of
VEGF-C. We find that s9Nrp2 forms a stable dimer
that potently inhibits VEGF-C/Nrp2 binding and
cellular signaling. These data provide critical insight
into VEGF-C/Nrp2 binding and inhibition.
INTRODUCTION
The vascular endothelial growth factor (VEGF) family of cytokines
are critical regulators of endothelial cell function. There are five
VEGF family members: VEGF-A, -B, -C, -D, and placental growth
factor (PlGF). Of these five, VEGF-C and VEGF-D selectively con-
trol lymphangiogenesis. While they show partially overlapping
biological activity and physical properties, VEGF-C is essential
for viability, whereas VEGF-D is not (Baldwin et al., 2005; Kark-
kainen et al., 2004). Endothelial cells of homozygous VEGF-C
knockoutmice do not sprout to form lymphatic vessels, which re-
sults in an alymphatic embryo and embryonic lethality (Karkkai-
nen et al., 2004). Overexpression of VEGF-C results in selective
induction of lymphatic but not vascular endothelial cell prolifera-
tion and lymphatic vessel enlargement (Jeltsch et al., 1997). In
addition to its critical physiological role, VEGF-C signaling is
also important for pathological lymphangiogenesis, which isStructure 23associated with both aberrant loss of function in lymphedema
(Saaristo et al., 2002) and gain of function in tumorigenesis and
metastasis (Caunt et al., 2008; Ellis, 2006; Stacker et al., 2002).
VEGF-C signals via the coordinated activity of two families of
endothelial cell surface receptors, the VEGF receptor (VEGFR)
family of receptor tyrosine kinases (RTK) (reviewed in Stuttfeld
and Ballmer-Hofer, 2009) and the Neuropilin (Nrp) family of cor-
eceptors (reviewed in Parker et al., 2012a). VEGF-C function is
specifically mediated through VEGFR-2/3 (Joukov et al., 1996;
Kukk et al., 1996; Lymboussaki et al., 1999) and Nrp2 (Karkkai-
nen et al., 2001; Xu et al., 2010), with VEGF-C capable of simul-
taneously engaging both families of receptors (Favier et al.,
2006). VEGFR-2/3 have dual functionality in both angiogenesis
and lymphangiogenesis (reviewed in Lohela et al., 2009). In
contrast, Nrp2 knockout mice display normal angiogenesis but
abnormal lymphatic vessel development (Yuan et al., 2002),
similar to the tissue-specific function observed in the VEGF-C
knockout (Karkkainen et al., 2004). Intriguingly, it has also been
demonstrated that Nrp2 can function in VEGF-C signaling inde-
pendent of its role as a coreceptor for VEGFR (Caunt et al., 2008).
Eachmember of the VEGF family of ligands is produced inmul-
tiple forms by either alternative splicing (e.g., VEGF-A, -B, and
PlGF) or proteolytic processing (e.g., VEGF-C and -D) (Holmes
and Zachary, 2005). In all cases, an invariant core cystine-knot
domain, which specifically interacts with VEGFR, is combined
with a variable C-terminal domain. VEGF-C is synthesized as a
proprotein with N- and C-terminal domains flanking the central
core cystine-knot domain. Prior to secretion, the C-terminal pro-
peptide is cleaved followed by extracellular cleavage of the N ter-
minus (Joukov et al., 1997). These processing events critically
alter both the physiological and pathological bioactivity of
VEGF-C (Siegfried et al., 2003). The mature dual-processed
VEGF-C shows dramatically enhanced stimulatory activity
in situ (McColl et al., 2003) and loss of C-terminal processing ab-
lates function in vivo (Khatib et al., 2010). However, the physical
basis for the enhanced activity of the mature form of VEGF-C re-
mains unclear and has been connected to different properties,
including differential receptor binding and interactions with hep-
arin/extracellular matrix (ECM) (Harris et al., 2013; Joukov et al.,
1997; Karpanen et al., 2006). The role of VEGF-C proteolytic
maturation in regulating Nrp2 binding is unknown.
The structural basis for VEGF-C binding to VEGFR-2/3 has
recently been elucidated and was shown to involve the invariant
cystine-knot domain of VEGF-C binding to the N-terminal, 677–687, April 7, 2015 ª2015 Elsevier Ltd All rights reserved 677
Figure 1. Crystal Structure of the VEGF-C/Nrp2 Complex Reveals the Basis for Proteolytic-Dependent Binding
(A) Organization of the VEGF-C proprotein and site of C-terminal processing (black arrow).
(B) Peptides corresponding to processed (green circle) and unprocessed (black triangle) VEGF-C were assayed for the ability to bind Nrp2-b1b2 as measured by
DSF thermal shift assay. Peptides were added to Nrp2-b1b2 to a final concentration of 0.5 mM and melting was monitored between 20C and 90C. All samples
were measured in triplicate, and a representative melting curve is shown for each. RFU, relative fluorescence units.
(C) Processed VEGF-C dose-dependently enhances the Nrp2-b1b2 Tm. Error bars indicate the SD of the three measurements.
(D) Structure of Nrp2-b1b2 (blue) in complex with the C terminus of VEGF-C (green).
(E) Cross-section of the Nrp2 binding pocket demonstrates that the free carboxy terminus of VEGF-C is buried against the Nrp2 C-wall, which is formed by the
third coagulation factor loop.domains of VEGFR-2 and VEGFR-3 (Leppanen et al., 2010,
2013). However, the structural basis for VEGF-C binding to
Nrp2 remains to be determined. Alternative splicing and proteol-
ysis modify the C-terminal variable region of VEGF and regulate
Nrp binding (Makinen et al., 1999; Parker et al., 2012c; Soker
et al., 1998). It has been demonstrated that Nrp1 binds the C-ter-
minal basic domain of the Semaphorin-3 (Sema3) and VEGF
family of ligands (He and Tessier-Lavigne, 1997; Soker et al.,
1996), utilizing a binding pocket for ligands that contain a C-ter-
minal arginine (Parker et al., 2010, 2012c; Vander Kooi et al.,
2007; von Wronski et al., 2006). Importantly, the Sema3 family
of ligands undergo furin-dependent proteolytic maturation within
their C-terminal domain, a process that liberates an extended
basic sequence and directly regulates bioactivity and Nrp bind-
ing (Adams et al., 1997; Parker et al., 2010, 2013).
Nrp2-dependent VEGF-C signaling is important in a variety
of tumors and overexpression of these factors is correlated
with advanced-stage disease and poor prognosis (Ellis, 2006;
Stacker et al., 2002). Thus, specific Nrp2/VEGF-C inhibitors are
of clinical interest. Soluble receptor fragments are common
endogenous inhibitors (Albuquerque et al., 2009; Ambati et al.,
2006; Kendall and Thomas, 1993; Rose-John and Heinrich,
1994). A soluble Nrp1 isoform was first identified as an endoge-
nous inhibitor of prostate cancer in vivo (Gagnon et al., 2000).
Soluble extracellular domain fragments can also be engineered
for use clinically, including VEGF-trap (Aflibercept), a chimeric
VEGFR-1/2-Fc fusion, which is an inhibitor of VEGF-A (Holash
et al., 2002). A soluble splice form of Nrp2, s9Nrp2, has been
identified at the transcript level (Rossignol et al., 2000). s9Nrp2
is produced by intron inclusion, which contains an in-frame
stop codon. This stop codon is located prior to the transmem-
brane domain and is thus predicted to produce a secreted
form of Nrp2. Interestingly, the insertion occurs in the middle of
the second coagulation factor domain (b2), rather than in an in-678 Structure 23, 677–687, April 7, 2015 ª2015 Elsevier Ltd All rightsterdomain region. The two Nrp2 coagulation factor domains
(b1b2) form an integral unit (Appleton et al., 2007), and thus,
the nature of the production and function of s9Nrp2 is unclear.
Further, domains b1b2 of Nrp2 have been demonstrated to
bind VEGF-C (Karpanen et al., 2006), bringing into question
whether this soluble splice form contains the structural require-
ments necessary to bind and sequester its ligands.
Here, we demonstrate that removal of the VEGF-C C-terminal
propeptide directly regulates binding to Nrp2. The structure of
the mature VEGF-C C terminus in complex with Nrp2 demon-
strates that a cryptic Nrp2-binding motif is liberated upon C-ter-
minal processing. This offers the first structural insight into the
physical basis for VEGF-C binding to Nrp2, showing that the pro-
teolytically liberatedC-terminal arginine of VEGF-Cdirectly binds
the Nrp2 b1 domain. Mutagenesis of both VEGF-C and Nrp2
confirms the critical nature of the VEGF-C C-terminal sequence
in Nrp2-b1 binding. Understanding the physical interactions un-
derlying VEGF-C/Nrp2 binding led us to consider mechanisms
for VEGF-C inhibition. The secreted Nrp2 splice form, s9Nrp2,
contains an intact Nrp2 b1 domain but a subsequent stop codon,
and we assessed its function as a pathway-specific inhibitor.
Strikingly, this soluble receptor forms a disulfide-linked dimer
with two tightly integrated b1 domains and functions as a potent
inhibitor of VEGF-C binding to Nrp2.
RESULTS
Structural Basis for Proteolytic-Dependent VEGF-C
Binding to Nrp2
VEGF-C is synthesized as a proprotein with N- and C-terminal
propeptides. Removal of the VEGF-C C-terminal propeptide crit-
ically regulates its bioactivity. C-terminal processing of VEGF-C
liberates a polypeptide stretch rich in basic amino acids that ter-
minates with a diarginine sequence (Figure 1A), a structural motifreserved
Table 1. Data Collection and Refinement Statistics
Construct Nrp2-VEGF-C Nrp2-T319R s9Nrp2
B
Data Collection
Beamline APS 22-ID APS 22-BM APS 22-ID
Wavelength 1.0000 1.0000 1.0000
Space group P21 P212121 P21212
Cell dimensions (A˚) 41.05, 120.81, 69.84 34.90, 70.76, 122.97 69.36, 91.39, 67.33
Cell dimensions () 90.0, 103.29, 90.0 90.0, 90.0, 90.0 90.0, 90.0, 90.0
Unique reflections 44,081 12,223 16,303
Completeness (%) 90.6 (82.0) 96.4 (83.2) 94.1 (79.8)
Resolution (A˚) 1.95 (2.02–1.95) 2.40 (2.49–2.40) 2.40 (2.49–2.40)
Rmerge (%) 9.9 (46.6) 8.0 (29.2) 9.9 (32.7)
Redundancy 5.1 (4.2) 6.8 (5.9) 4.4 (4.1)
I/s(I) 13.1 (3.0) 29.4 (5.1) 12.3 (3.2)
Refinement
Resolution limits (A˚) 20.00 (1.95) 20.00 (2.40) 20.00 (2.40)
No. reflections/no. to compute Rfree 41,511/2,140 11,490/586 15,439/821
R(Rfree) 21.0 (24.1) 20.1 (25.5) 21.0 (26.4)
No. protein residues 632 313 361
No. solvent/ion molecules 333 123 107
Root-mean-square deviation bond (A˚) 0.006 0.008 0.006
Root-mean-square deviation angle () 1.11 1.19 1.04
Protein Geometry
Ramachandran outlier/favored (%) 0/96.7 0/96.1 0/96.7
Residues with bad bonds/angles 0/0 0/0 0/0
Rotamer outliers 0 0 0conserved across the VEGF and Sema3 family of ligands and
known to be important for Nrp1 binding. Thus, we hypothesized
that processing of VEGF-Cmay directly regulate a physical inter-
action with Nrp2. To test this hypothesis, we produced peptides
corresponding to the unprocessed (215-RQVHSIIRRSLPA-227)
and processed (215-RQVHSIIRR-223) VEGF-C C terminus and
measured the ability of each peptide to bind Nrp2 domains
b1b2 using a differential scanning fluorimetry (DSF) thermal shift
assay (Figure 1B). Processed VEGF-C significantly stabilized
Nrp2-b1b2 (Tm 48.8
C ± 0.06C to 50.3C ± 0.05C), while un-
processed VEGF-C showed no effect (Tm 48.4
C ± 0.04C).
Further, the processed VEGF-C peptide showed dose-depen-
dent saturable binding to Nrp2-b1b2 with an apparent dissocia-
tion constant KD = 199 mM ± 71 mM (Figure 1C). These data
demonstrate that C-terminal proteolytic maturation directly reg-
ulates VEGF-C binding to Nrp2.
To define the physical basis for proteolytic-dependent binding
of VEGF-C to Nrp2, we determined the crystal structure of the
processed VEGF-C C terminus in complex with Nrp2 domains
b1b2. The C-terminal five amino acids of mature VEGF-C (219-
SIIRR-223), which are strictly conserved across species and
also with VEGF-D, were fused to the C terminus of human Nrp2
domains b1b2 (residues 276–595). The fusion protein was ex-
pressed in Escherichia coli, purified, and crystallized. The struc-
ture was solved by molecular replacement and was refined to
a resolution of 1.9 A˚ (Figure 1D; Table 1). There were two mole-
cules in the asymmetric unit oriented in an antiparallel fashionStructure 23(Figure S1A). Both molecules demonstrated specific binding of
the VEGF-C encoded residues via an intermolecular interaction
with a symmetry-related molecule.
Analysis of the structure reveals that VEGF-C (green) engages
a binding pocket formed by the Nrp2-b1 (blue) coagulation factor
loops (Figures 1D, S1B, and S1C). Indeed, this interloop cleft
uniquely accommodates the C-terminal residue of processed
VEGF-C (Figure 1E). The free carboxy terminus of VEGF-C is in-
tegrated into the binding pocket through interactions with resi-
dues from the third coagulation factor loop (L3) of Nrp2-b1,
which form a wall at one side of the binding pocket (C-wall). Spe-
cifically, an extensive hydrogen bond network forms between
the VEGF-C-free C-terminal carboxylate and the side chains of
the C-wall residues S349, T352, and Y356 (Figure 1E). Impor-
tantly, the position of the C-wall would preclude binding of
the unprocessed protein, providing a physical mechanism
for the observed proteolytic-dependent binding of VEGF-C to
Nrp2-b1b2.
Characterization of the VEGF-C/Nrp2 Interaction
Clear electron density for the VEGF-C-encoded region was
observed, permitting modeling of both the VEGF-C polypeptide
and interfacing solvent that bridge the twomolecules (Figure 2A).
Analysis of the VEGF-C/Nrp2 interface reveals direct interactions
between VEGF-C and residues within the L1, L5, and L3 loops of
Nrp2-b1 (Figure 2B), the regions that show the largest conforma-
tional changes when comparing the bound structure with the, 677–687, April 7, 2015 ª2015 Elsevier Ltd All rights reserved 679
Figure 2. Mechanism of VEGF-C Binding to Nrp2
(A) Zoom of the intermolecular interface between Nrp2 (blue) and VEGF-C (green) with the 2Fo  Fc electron density map for VEGF-C contoured at 1.0s.
Interfacing water is shown as gray spheres.
(B) Ligplot+ generated representation of the interaction between VEGF-C (green) and Nrp2 (blue). Bond distances (A˚) are labeled in black, and water is shown
as gray spheres.
(C) Nrp2 binding was compared between VEGF-C and VEGF-C R223E. Binding was measured in triplicate and is reported as mean ± SD (*p < 0.05). WT,
wild-type.
(D) Superimposition of the VEGF-A HBD/Nrp1 complex (PDB 4DEQ) and the tuftsin/Nrp1 complex (PDB 2ORZ) onto the structure of the VEGF-C/Nrp2 complex
demonstrates the shared and unique modes of engagement within this ligand/receptor family.previously reported apo structure (Figure S2) (Appleton et al.,
2007). In addition to the hydrogen bond network formed be-
tween the VEGF-C free carboxy terminus and the Nrp2 L3
loop, the side chain of the VEGF-C C-terminal arginine, R223,
forms extensive interactions with the Nrp2 binding pocket. The
guanidinium of VEGF-C R223 forms a salt bridge with the
Nrp2-b1 L5 loop residue D323. In addition, the aliphatic portion
of the R223 side chain displays extensive van der Waals interac-
tions with two tyrosine residues of Nrp2-b1 that demarcate the
sides of the binding pocket, Y299 (L1 loop) and Y356 (L3 loop).
In addition to interactions mediated by VEGF-C R223, there is
a hydrogen bond between the backbone carbonyl of I221 and
the aromatic hydroxyl of Nrp2 Y299.
While protein-protein binding is primarily mediated by direct
interactions between polypeptide chains, interfacing solvent
also plays a critical role in stabilizing protein-protein complexes
(Janin, 1999; Karplus and Faerman, 1994). Three water mole-
cules, two of which bridge the interaction between VEGF-C
and Nrp2, are observed in the binding site. One solvent molecule
facilitates a water-mediated hydrogen bond between the side
chain hydroxyl of Nrp2 T319, located at the base of the binding
pocket, and the side chain guanidinium of VEGF-C R223 (Fig-
ure 2B). Likewise, a second solvent molecule bridges the side
chain carboxylate of Nrp2 E351 and the free carboxylate of
VEGF-C. These solvent-mediated interactions appear to further
stabilize the position of the VEGF-C C terminus within the
Nrp2-b1 binding pocket.
To confirm the critical role of the VEGF-C C terminus, we
mutated the C-terminal arginine of VEGF-C to glutamate
(R223E) and compared the ability of alkaline phosphatase (AP)-
tagged VEGF-C and VEGF-C R223E to bind Nrp2-b1b2 affinity
plates (Figure 2C). Robust binding was observed between AP-
VEGF-C and Nrp2-b1b2, but R223E binding was reduced by
>95%. These data demonstrate that the C-terminal arginine of
mature VEGF-C is necessary for high-affinity Nrp2-b1b2 binding
and confirm the importance of C-terminal propeptide processing680 Structure 23, 677–687, April 7, 2015 ª2015 Elsevier Ltd All rightswithin VEGF-C to produce a C-terminal arginine that allows avid
engagement of Nrp2.
The interaction observed between Nrp2-b1 and VEGF-C bur-
ies 374 A˚2 surface area of the VEGF-C C terminus. This is com-
parable with that observed for the exon 8 encoded residues of
VEGF-A (338 A˚2 buried surface area) (Figure 2D, dark gray)
(Parker et al., 2012c) and tuftsin (328 A˚2 buried surface area) (Fig-
ure 2D, light gray) (Vander Kooi et al., 2007) which complex with
an equivalent binding site on Nrp1-b1. Importantly, these li-
gands, like VEGF-C, also contain a C-terminal arginine. All three
ligands traverse the L1 loop, an orientation that is maintained by
the engagement of the carboxy terminus by the C-wall. Collec-
tively, the shared use of a C-terminal arginine in VEGF-A and
VEGF-C explains their ability to bind both Nrp receptors (Karpa-
nen et al., 2006; Parker et al., 2012b), while electrostatic repul-
sion by the L1 loop and adjacent regions account for receptor
selectivity (Figure 2D) (Parker et al., 2012b, 2012c).
Occluding the Nrp2 Interloop Cleft Abolishes Binding
The structure of VEGF-C in complex with Nrp2 reveals a critical
role for the Nrp2-b1 interloop cleft, which forms the VEGF-C
binding pocket. To confirm that the Nrp2 binding pocket is
responsible for VEGF-C binding, we carried out site-directed
mutagenesis of Nrp2-b1b2 to generate a construct with an
occluded binding pocket. Specifically, T319, a residue at the
base of the Nrp2-b1 interloop cleft, was mutated to arginine
(Nrp2-T319R). We determined the crystal structure of Nrp2-
T319R to a resolution of 2.4 A˚ (Figure 3A; Table 1). The R319
side chain showed clear electron density extending into the inter-
loop cleft between the two binding pocket tyrosines, Y299 and
Y356 (Figure 3B). Superimposing the VEGF-C/Nrp2 complex
onto Nrp2-T319R demonstrates that the binding site occupied
by VEGF-C is occluded in the Nrp2 mutant (Figure 3C). The
Nrp2-T319R mutant was then used to analyze the contribution
of the interloop cleft to VEGF-C binding. We compared the bind-
ing of VEGF-C with Nrp2-b1b2 and Nrp2-T319R (Figure 3D).reserved
Figure 3. Crystal Structure and VEGF-C Binding Properties of Nrp2-
T319R
(A) Structure of Nrp2-T319R with the stick representation for T319R shown in
red.
(B) Zoom of the Nrp2-T319R binding pocket. The blue mesh illustrates the
2Fo  Fc electron density map for R319 contoured at 1.0s.
(C) Superimposition of VEGF-C (green) onto the structure of Nrp2-T319R
demonstrates that the binding pocket normally occupied by VEGF-C is
blocked in the mutant.
(D) VEGF-C binding was compared between Nrp2-b1b2 and Nrp2-T319R.
Binding was measured in triplicate and is reported as mean ± SD (*p < 0.05).While robust binding was observed between AP-VEGF-C and
Nrp2-b1b2, binding to Nrp2-T319R was completely abolished.
These data confirm that the interloop cleft, formed by the
Nrp2-b1 coagulation factor loops, forms a structure that uniquely
accommodates the C terminus of VEGF-C to mediate binding of
the C-terminally processed ligand.
A Dimeric Soluble Nrp2 Splice Form
Based on the specific binding of VEGF-C to the Nrp2 b1 domain,
we hypothesized that the previously identified splice form of
Nrp2, s9Nrp2, could function as a selective inhibitor of VEGF-C.
s9Nrp2 is an alternative Nrp2 splice form that arises from intron
inclusion in the b2 domain (Figure 4A). An in-frame stop codon
encoded within the intron is predicted to result in termination
of translation prior to the transmembrane domain, and thus pro-
duction of a secreted Nrp2 receptor that contains the first two
CUB domains (a1 and a2) and the first coagulation factor domain
(b1), but only a portion of the coding sequence for the second
coagulation factor domain (b2). Given that the b1 domain of
Nrp2 is solely responsible for VEGF-C binding, we hypothesized
that s9Nrp2 may be able to effectively sequester VEGF-C,
thereby functioning as an inhibitor. However, it is unknownStructure 23whether the s9Nrp2 transcript produces a functional protein,
since s9Nrp2 retains residues coding only a portion of the b2
domain (114 of 159 residues). Indeed, s9Nrp2 lacks the coding
region for three of the eight core b strands that normally integrate
to form the distorted jelly-roll fold that typifies the b1 and b2 do-
mains of Nrp. In addition, it was unknown whether s9Nrp2 could
accommodate the loss of the canonical C-terminal capping
cysteine of the b2 domain. To investigate the physical and func-
tional activity of s9Nrp2, we tested the ability of this isoform to be
secreted from eukaryotic cells. We produced s9Nrp2 and a
construct containing solely the ligand binding coagulation factor
domains, s9Nrp2
B (Figure 4A), as a human growth hormone
(Hgh)-fusion in Chinese hamster ovary (CHO) cells. Western
blot analysis demonstrated that both constructs were efficiently
produced and secreted (Figure 4B). We next produced s9Nrp2
B
protein in bacteria. Analysis of s9Nrp2
B by reducing SDS-PAGE
revealed that purified s9Nrp2
B, while running with a larger
apparent molecular weight (MW) than Nrp2-b1 alone, was
smaller than expected from its primary sequence (Figure 4C,
observed MW = 22 kDa, expected MW = 34 kDa). Mass spec-
trometry confirmed that s9Nrp2
B is an essentially homogeneous
single species with MW = 22,775 Da ± 20 Da. These data,
together with the observed intact N-terminal His-tag, indicate
that s9Nrp2
B is cleaved C-terminal to E457 (predicted MW =
22,792 Da). Thus, the proteolyzed s9Nrp2
B contains only a single
cysteine residue from the b2 domain (C434), which normally
forms an intradomain disulfide. Surprisingly, under nonreducing
conditions, s9Nrp2
B ran with an apparent MW = 38 kDa, indi-
cating the formation of a disulfide-linked intermolecular dimer
via the free b2 domain cysteine (Figure 4C). Predominantly disul-
fide-linked dimeric protein is also observed in s9Nrp2
B protein
purified from CHO-cell conditioned media (Figure S3A). The dif-
ference in oligomeric state was evident from size exclusion
chromatography (SEC) (Figure 4D). Nrp2-b1 eluted off SEC
with an apparent MW = 16 kDa (gray line), while s9Nrp2
B had
an apparent MW = 38 kDa (black line), consistent with the
SDS-PAGE analysis.
s9Nrp2
B Is a Uniquely Potent Inhibitor of VEGF-C/Nrp2
Binding
To understand the structural arrangement of the s9Nrp2
B dimer,
we determined the crystal structure of s9Nrp2
B to a resolution of
2.4 A˚ (Figure 5A; Table 1). Continuous electron density was
observed from F275 to S453, consistent with the C terminus
defined using mass spectrometry. A single dimer was present
in the asymmetric unit, with the base of each b1 domain apposed
to the other, thus forming an extended antiparallel dimer. The
orientation of the dimer is stabilized by both the intermolecular
disulfide and, unexpectedly, a unique dimeric helical bundle
formed by residues from the b1-b2 linker and b2 domain (Fig-
ure 5B). The residues that form this unique helix (residues 428–
453) display dramatic structural reorganization relative to that
observed in the intact b2-domain, where they form an extended
sheet and loop motif (Figure 5C). The C-terminal helix runs
approximately 20 off parallel from the base of the b1 domain,
an angle that is maintained by a cluster of hydrophobic residues
at the hinge region between the helix and domain b1. The helix
both caps the b1 domain and mediates the intermolecular inter-
action interface with the other monomer of the s9Nrp2
B dimer., 677–687, April 7, 2015 ª2015 Elsevier Ltd All rights reserved 681
Figure 4. s9Nrp2
B Forms a Disulfide-Linked
Dimer
(A) Domain organization of Nrp2, s9Nrp2, and the
protein fragment used for our studies, s9Nrp2
B.
The intron 9-encoded sequence is indicated,
which includes the in-frame stop codon (*).
(B) Western blot analysis of Hgh-tagged s9Nrp2
and s9Nrp2
B expressed in CHO cells.
(C) Nonreducing and reducing SDS-PAGE anal-
ysis of Nrp2-b1 and s9Nrp2
B.
(D) The oligomeric state of s9Nrp2
B (black line) was
analyzed by size exclusion chromatography.
Nrp2-b1 was run as a reference (gray line).The intermolecular interface is composed of both helix-helix in-
teractions, which are mostly hydrophobic in nature (Figure 5B),
and helix-b1 interactions, which are mostly hydrophilic in nature.
Truncation of the helix decreased the amount of dimeric species
formed, demonstrating a role for the helix in the formation of a
stable disulfide-linked dimer (Figure S3B).
The two binding pockets within the s9Nrp2
B dimer are posi-
tioned 71 A˚ apart, suggesting that it could simultaneously
engage both subunits of the VEGF-C dimer, which is 68 A˚ wide
(Leppanen et al., 2010). Thus, we hypothesized that coengage-
ment of both VEGF-C monomers by s9Nrp2
B would allow the
dimer to function as a uniquely potent inhibitor of VEGF-C/
Nrp2 binding. To test this hypothesis, we compared the inhibi-
tory potency of ATWLPPR, an optimized peptide inhibitor of
Nrp that functions by competitive binding (Parker and Vander
Kooi, 2014; Starzec et al., 2007), with Nrp2-b1 and s9Nrp2
B,
both of which function as soluble competitors through seques-
tration of VEGF-C (Figure 5D). ATWLPPR showed dose-depen-
dent inhibition of VEGF-C binding to Nrp2 with an inhibitory
concentration 50% (IC50) = 10 mM (gray line), consistent with
its modest reported potency. Next, we examined the ability of
Nrp2-b1 to inhibit binding (blue line). Nrp2-b1 sequestered
VEGF-C with improved potency compared with the peptide in-
hibitor, with an IC50 = 1.5 mM. As expected for a monomeric
competitive inhibitor, the Hill slope was approximately –1
(ATWLPPR = –1.08 andNrp2-b1 = –0.97). These data are consis-
tent with independent engagement of each VEGF-C monomer
by a single Nrp2-b1. Next, we measured the inhibitory potency
of s9Nrp2
B (orange line). Strikingly, s9Nrp2
B potently seques-
tered VEGF-C with an IC50 = 250 nM, a significant improvement
in potency from both the peptide inhibitor and Nrp2-b1. In addi-
tion, the Hill slope for s9Nrp2
B was –1.5. Thus, the enhanced po-
tency of s9Nrp2
B is due to its ability to synergistically sequester682 Structure 23, 677–687, April 7, 2015 ª2015 Elsevier Ltd All rights reservedthe VEGF-C dimer through simultaneous
and cooperative engagement of the two
VEGF-C monomers.
VEGF-C signaling requires the coordi-
natedaction ofNrp2and theRTKVEGFR3
(Xu et al., 2010). Nrp2 enhances signaling
via VEGF-C through both a direct interac-
tion with VEGF-C and via coupling with
VEGFR3 (Favier et al., 2006). Thus, while
s9Nrp2
B could inhibit VEGF-C signaling
by sequestering VEGF-C ligand from
Nrp2, it is also possible that s9Nrp2
Bcould interact with VEGFR3 and actually enhance VEGF-C bind-
ing and signaling. Therefore, we tested the effect of s9Nrp2
B on
VEGF-C binding to VEGFR3. While s9Nrp2
B blocked VEGF-C
binding to Nrp2, it showed no effect on VEGF-C binding to
VEGFR3, indicating that the binding events are independent
(Figure 5E).
We extended our studies to assess the efficacy of s9Nrp2
B
as an inhibitor of Nrp2 signaling in prostate cancer. Nrp2 and
VEGF-C expression have both been reported to function in the
survival and aggressiveness of prostate cancer (Goel et al.,
2012; Muders et al., 2009). We assessed the ability of Nrp inhibi-
tion to reduce the formation of prostatospheres by C4-2 cells.
Incubation with s9Nrp2
B resulted in a significant decrease in
prostatosphere formation (Figure 5F). Incubation with the spe-
cific Nrp inhibitor C-furSema (Goel et al., 2013; Parker et al.,
2010) likewise significantly reduced prostatosphere formation,
whereas the control C-Sema did not, demonstrating the specific
role for Nrp in prostatosphere formation. These data demon-
strate that s9Nrp2
B can effectively sequester VEGF-C and raises
the exciting possibility of using engineered Nrp ectodomains as
inhibitors of pathological Nrp-dependent signaling (Figure 5G).
DISCUSSION
Structural characterization of the mechanism for VEGF-C bind-
ing to Nrp2 represents an important step for understanding the
physiological and pathological activity of VEGF-C. These data
also inform the rational design of specific VEGF-C/D antago-
nists, including s9Nrp2
B, which potently inhibits VEGF-C/Nrp2
binding and represents a potential therapeutic avenue. Collec-
tively, these results have important implications for interpreting
both the aberrant loss and gain of function in the VEGF-C/Nrp2
signaling axis that critically underlies a number of disease states.
Figure 5. Crystal Structure and Inhibitory Properties of s9Nrp2
B
(A) Crystal structure of the s9Nrp2
B dimer (chain A, light orange; chain B, dark orange). The intermolecular disulfide is shown in black and the Nrp2-b1 binding
pockets are labeled with arrows.
(B) Zoom of the dimeric helical bundle with the 2Fo  Fc electron density map contoured at 1s.
(C) The residues of the Nrp2 b1-b2 linker and b2 domain show a dramatic structural reorganization from an extended loop in the b1b2 sequence (blue) to an
extended helix in the s9Nrp2
B dimer (orange).
(D) ATWLPPR (gray), Nrp2-b1 (blue), and s9Nrp2
B (orange) were assayed for the ability to inhibit VEGF-C binding to Nrp2. ATWLPPR inhibited binding with
an IC50 = 10 mM (log[IC50] =4.98 ± 0.03), Nrp2-b1 inhibited binding with an IC50 = 1.5 mM (log[IC50] =5.82 ± 0.09), and s9Nrp2B inhibited binding with an IC50 =
250 nM (log[IC50] = 6.60 ± 0.08).
(E) s9Nrp2
Bwas assayed for the ability to alter VEGF-C binding to VEGFR3. Addition of 4 mMs9Nrp2
B fully inhibited VEGF-C/Nrp2 binding but showed no effect on
VEGF-C/VEGFR3 binding.
(F) Inhibition of C4-2 cell prostatosphere formation was used to assess the biological activity of s9Nrp2
B. Prostatosphere formation was compared in the absence
and presence of s9Nrp2
B, as well as with C-furSema (positive control) and C-Sema (negative control).
(G) Model illustrating the mechanism of action for s9Nrp2
B. s9Nrp2
B sequesters VEGF-C and prevents activation of the VEGFR3/Nrp2 signaling complex. All
inhibition experiments were measured in triplicate and reported as mean ± SD (*p < 0.05).With complementary biochemical and structural approaches,
we show that VEGF-C C-terminal proteolysis is required for Nrp2
binding. The requirement for proteolytic processing is deter-
mined by the position of the Nrp2 C-wall, formed by the L3 coag-
ulation factor loop residues, which specifically engages the
VEGF-C free carboxy terminus, precluding binding of unpro-
cessed protein. These results provide critical insight for inter-
preting the altered in vitro and in vivo functionality of alternative
VEGF-C forms. While both N- and C-terminal processing regu-
late VEGF-C activity (Joukov et al., 1997; McColl et al., 2003),
processing at these sites is not functionally equivalent. Indeed,
loss of C-terminal processing is uniquely detrimental, fully
ablating VEGF-C function in vivo (Khatib et al., 2010), which we
demonstrate blocks Nrp2 binding.Structure 23The loss of VEGF-C binding to Nrp2-T319R, a mutant with an
occluded binding pocket, demonstrates the use of a C-terminal
arginine for ligand engagement. Indeed, the VEGF-C C-terminal
arginine side chain and free carboxylate form extensive interac-
tions with the Nrp2-b1 binding pocket. Interestingly, VEGF-C is
not the only VEGF family member that, in the absence of post-
translational modification, lacks a C-terminal arginine. Of the
five VEGF family members, three contain Nrp binding domains
that lack this structural motif (VEGF-C, VEGF-D, and VEGF-
B186). VEGF-D, a close structural and functional homolog of
VEGF-C, is processed at an equivalent site in its C terminus to
produce a C-terminal arginine (Stacker et al., 1999) and thus
likely utilizes a similar binding mode to Nrp2. This observation
provides additional functional insight, as loss of VEGF-D, 677–687, April 7, 2015 ª2015 Elsevier Ltd All rights reserved 683
C-terminal processing also ablates function in vivo (Harris et al.,
2013). There are three VEGF-B isoforms, VEGF-B167, VEGF-
B127, and VEGF-B186, all of which differ in their C-terminal
domain (Olofsson et al., 1996a, 1996b). Characterization of
VEGF-B186 demonstrated that it exhibited proteolytic-depen-
dent binding to Nrp1 and identified the site of proteolysis as
R227 (Makinen et al., 1999). Thus, the mechanism of proteo-
lytic-dependent VEGF-C binding to Nrp2 has broad explanatory
power for understanding Nrp binding across the VEGF family.
Determining the structural basis for VEGF-C signaling via Nrp2
informs ongoing studies to describe the effect of signaling defi-
ciency on human disease. Deficient VEGF-C signaling via Nrp2
has significant implications for both primary and secondary lym-
phedema. Mutations in both VEGFR-3 (Karkkainen et al., 2000)
and VEGF-C (Gordon et al., 2013) have been demonstrated to
underlie hereditary lymphedema and Nrp2 has been identified
as an additional candidate gene (Ferrell et al., 2008; Karkkainen
et al., 2001). In addition, both VEGF-C and Nrp2 have recently
been identified as candidate genes for the development of sec-
ondary lymphedema following surgery in breast cancer (Mia-
skowski et al., 2013). The structural insights gleaned from the
VEGF-C/Nrp2 complex also provide an important molecular ba-
sis for interpreting emerging exome sequencing data that has
identified Nrp2 variants in close proximity to the ligand binding
interface. Intriguingly, a stringent examination of exome se-
quencing data has reported both common and rare Nrp2 vari-
ants in human populations (Tennessen et al., 2012). Several of
these variants are located in the coagulation factor loops of
Nrp2-b1, the region to which VEGF-C binds. Specifically, there
are two reported variants in the L5 loop (N321I and L322M),
which are located proximal to the critical salt bridge formed by
D323, and two in the L3 loop (Q353H and N354K). The structural
data presented here provide a rationale for examining specific
coagulation factor loop variants for loss of function on both a
physical and functional level.
As opposed to aberrant VEGF-C loss of function in lymphe-
dema, aberrant activation of VEGF-C signaling via Nrp2 is asso-
ciated with cancer initiation, survival, and progression (Ellis,
2006; Stacker et al., 2002). The Nrp2/VEGF-C signaling axis con-
tributes to tumorigenesis via multiple mechanisms. Mimicking its
physiological function, VEGF-C signaling via Nrp2 stimulates
lymphatic vessel recruitment to tumors and directly contributes
to cancer metastasis (Caunt et al., 2008). Importantly, the role
of VEGF-C and Nrp2 in tumorigenesis is not exclusively associ-
ated with aberrant lymphangiogenesis. Indeed, in situ studies
have demonstrated that autocrine VEGF-C signaling in breast
cancer cells stimulates cellular motility (Timoshenko et al.,
2007). Further, recent reports indicate that cancer cell survival
is enhanced through VEGF-C/Nrp2-dependent autophagy
(Stanton et al., 2012) and that autocrine Nrp2 signaling maintains
the population of cancer stem cells (Goel et al., 2013). VEGF-C
also functions to protect prostate cancer cells from oxidative
stress in an Nrp2-dependent fashion (Muders et al., 2009).
Thus, selective inhibition of Nrp2 represents a promising, multi-
pronged anticancer therapeutic strategy.
Secreted splice forms of angiogenic receptors have essential
roles in vivo (Albuquerque et al., 2009; Ambati et al., 2006; Ken-
dall and Thomas, 1993) and have been engineered to serve as
therapeutic inhibitors that block aberrant pathway activation by684 Structure 23, 677–687, April 7, 2015 ª2015 Elsevier Ltd All rightsligand sequestration (Stewart, 2012). Here, we demonstrate
that the alternative Nrp2 splice form, s9Nrp2
B, potently seques-
ters VEGF-C and inhibits binding to Nrp2. The biological function
and localized tissue-specific expression of s9Nrp2 are of sig-
nificant interest. Indeed, s9Nrp2 may be analogous or comple-
mentary to sVEGFR-2, the secreted splice form of VEGFR-2
that functions as an endogenous lymphangiogenesis inhibitor
(Albuquerque et al., 2009). VEGF-D also functions in lymphatic
angiogenesis and has been shown to have partially overlapping
biological functionwith VEGF-C and important pathological func-
tions (Haiko et al., 2008; Harris et al., 2013; Karpanen et al., 2006).
The conservation of Nrp2-interacting residues between VEGF-C
and VEGF-D strongly suggests that s9Nrp2
B will equivalently
sequester both VEGF-C and VEGF-D. In contrast, the heparin-
binding domain of VEGF-A contains specificity determinants
that limit binding to Nrp2 (Parker et al., 2012b, 2012c). Thus,
s9Nrp2
B is likely to selectively sequester the lymphangiogenic-
specific VEGF family members, VEGF-C and VEGF-D.
The practice of engineering inhibitormultimerization to increase
potency is well established for soluble receptor fragments. Most
commonly, soluble receptors are dimerized by expression as an
Fc fusion protein (e.g., VEGF-trap). s9Nrp2
B represents a unique
mechanism for generation of a multimeric protein that maintains
the benefits of avidity but does not require introduction of an
exogenous polypeptide sequence. Additional optimization of
s9Nrp2
B potency, selectivity, and stability is an important future
direction for the development of a therapeutically useful inhibitor.
EXPERIMENTAL PROCEDURES
Protein Expression and Purification
Human Nrp2-b1b2 (residues 276–595), human Nrp2-b1 (residues 276–430),
human Nrp2-T319R (residues 276–595 with T319R mutation), s9Nrp2
B (resi-
dues 275–555: isoform O60462-6), s9Nrp2
B-D-helix (residues 276–436), and
the Nrp2-b1b2/VEGF-C fusion were expressed in E. coli as His-tag fusion pro-
teins from pET28b (Merck). Proteins were purified via immobilizedmetal ion af-
finity chromatography (IMAC) and either heparin affinity or SEC. AP-VEGF-C
(residues 108–223) wild-type and mutant and Hgh-tagged proteins were pro-
duced by transient transfection of CHO cells (Aricescu et al., 2006). The
VEGFR-3 extracellular domain was produced via baculovirus-mediated
expression (residues 21–776) and purified by IMAC and SEC.
Structure Determination
Purified Nrp2-b1b2-VEGF-C fusion, Nrp2-T319R, and s9Nrp2
B were concen-
trated to 2.0 mg/ml, 2.1 mg/ml, and 3.5 mg/ml, respectively, and crystals
grown by hanging-drop vapor-diffusion experiments. Fusion protein crystals
were obtained in 2 weeks at room temperature (RT) in 0.1 M MES (pH 6.5),
0.5 M ammonium sulfate. Nrp2-T319R crystals were obtained in 5 days at
RT in 0.1 M HEPES (pH 7), 18% (w/v) PEG 12000. s9Nrp2
B crystals were ob-
tained in 2 weeks at RT in 10% PEG 1000/10% PEG 8000. Crystals were
passed through mother liquor supplemented with 10% glycerol and then flash
frozen in liquid nitrogen. Diffraction data were collected at the SER-CAT 22-ID
and 22-BM beamlines of the Advanced Photon Source, Argonne National Lab-
oratories and processed using HKL2000 (Otwinowski and Minor, 1997). Struc-
tures were solved by molecular replacement using Nrp2-b1b2 (PDB 2QQJ)
followed by iterative modeling building and refinement using COOT (Emsley
et al., 2010) and Refmac5 (Murshudov, 1997) to generate a final refined model
(Table 1).
DSF
Peptides corresponding to processed and unprocessed VEGF-C were pro-
duced with an N-terminal tryptophan to allow accurate quantitation by UV280
absorbance (LifeTein LLC). Peptides were resuspended and combined withreserved
2 mM of Nrp2-b1b2 and 5x SYPRO Orange Protein Gel Stain (Life Technolo-
gies) in PBS. Nrp2-b1b2 melting was monitored on a CFX96 Real-Time PCR
system (Bio-Rad) from 20C to 90C at a rate of 1C/50 swith fluorescent read-
ings taken every 1C.
Binding and Inhibition Assays
Plate binding and soluble Nrp competition assays were performed by
measuring the binding of AP-tagged VEGF-C to Nrp2-b1b2, Nrp2-T319R, or
VEGFR3 affinity plates. For direct binding assays, ligand was directly added
to Nrp2-affinity plates, incubated for 1 hr at RT, washed, and developed using
p-nitrophenyl phosphate AP substrate. For competition experiments, ligand
was premixed with inhibitor and then added to affinity plates as with binding.
Prostatosphere Assays
Prostatosphere cultures used C4-2 prostate cancer cells (UroCor) (Cao et al.,
2011). 5,000 cells/well were cultured in suspension in serum-free DMEM-F12
(Life Technologies), supplementedwith B27 (1:50, Life Technologies), 20 ng/ml
epidermal growth factor (Peprotech), and 4 mg/ml insulin (Sigma-Aldrich) in
6-well ultralow attachment plates (Corning). s9Nrp2
B, C-furSema, or C-Sema
inhibitors were added at a concentration of 5.0 mM while plating the cells.
The prostatospheres were cultured for 6 days, and 1 ml of culture medium
was added every other day. Spheres larger than 100 mm were counted.
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